MXPA01010625A - Metodo para regulacion por disminucion de la actividad de interleucina 5. - Google Patents

Metodo para regulacion por disminucion de la actividad de interleucina 5.

Info

Publication number
MXPA01010625A
MXPA01010625A MXPA01010625A MXPA01010625A MXPA01010625A MX PA01010625 A MXPA01010625 A MX PA01010625A MX PA01010625 A MXPA01010625 A MX PA01010625A MX PA01010625 A MXPA01010625 A MX PA01010625A MX PA01010625 A MXPA01010625 A MX PA01010625A
Authority
MX
Mexico
Prior art keywords
regulating
activity
Prior art date
Application number
MXPA01010625A
Other languages
English (en)
Inventor
Steen Klysner
Original Assignee
Pharmexa As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa As filed Critical Pharmexa As
Publication of MXPA01010625A publication Critical patent/MXPA01010625A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5409—IL-5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MXPA01010625A 1999-04-23 2000-04-19 Metodo para regulacion por disminucion de la actividad de interleucina 5. MXPA01010625A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199900552 1999-04-23
US13281199P 1999-05-06 1999-05-06
PCT/DK2000/000205 WO2000065058A1 (en) 1999-04-23 2000-04-19 Method for down-regulating il5 activity

Publications (1)

Publication Number Publication Date
MXPA01010625A true MXPA01010625A (es) 2003-09-04

Family

ID=26064209

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01010625A MXPA01010625A (es) 1999-04-23 2000-04-19 Metodo para regulacion por disminucion de la actividad de interleucina 5.

Country Status (19)

Country Link
US (2) US7285273B1 (es)
EP (1) EP1173573A1 (es)
JP (1) JP2002543098A (es)
KR (1) KR20020084841A (es)
CN (1) CN1355846A (es)
AU (1) AU777952B2 (es)
CA (1) CA2370391A1 (es)
CZ (1) CZ20013709A3 (es)
EA (1) EA200101125A1 (es)
EE (1) EE200100552A (es)
HR (1) HRP20010824A2 (es)
HU (1) HUP0200958A3 (es)
IL (1) IL145786A0 (es)
MX (1) MXPA01010625A (es)
NO (1) NO20015021L (es)
PL (1) PL351986A1 (es)
SK (1) SK14832001A3 (es)
TR (1) TR200103046T2 (es)
WO (1) WO2000065058A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7097837B2 (en) 2001-02-19 2006-08-29 Pharmexa A/S Synthetic vaccine agents
RU2319503C2 (ru) * 2001-11-07 2008-03-20 Цитос Байотекнолоджи Аг Композиция для иммунизации (варианты), способ ее получения и применение для лечения аллергических эозинофильных заболеваний
IL161147A0 (en) * 2001-11-07 2004-08-31 Cytos Biotechnology Ag Antigen arrays presenting il-5, il-3, or eotaxin for treatment of allergic eosinophilic diseases
KR20050044857A (ko) * 2001-11-16 2005-05-13 파멕사 에이/에스 무차별 ｔ 세포 에피토프 삽입물을 갖는 멀티머 단백질의면역원성 모방체
TW200407162A (en) * 2002-08-30 2004-05-16 Glaxo Group Ltd Vaccine
JP2006503018A (ja) * 2002-08-30 2006-01-26 グラクソ　グループ　リミテッド ワクチン
KR20060010730A (ko) * 2003-03-24 2006-02-02 메르시아 파마, 아이엔씨. 염증 상태를 치료하고 예방하기 위한 방법과 조성물
CN103091499B (zh) * 2013-01-23 2015-07-08 三峡大学 一种肿瘤标志物钙网蛋白检测试剂盒的制备及应用
US10154658B2 (en) * 2013-02-22 2018-12-18 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
EP2967014B1 (en) * 2013-03-11 2019-10-16 Regeneron Pharmaceuticals, Inc. Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules
CN113307870B (zh) * 2020-10-30 2022-12-23 上海洛启生物医药技术有限公司 抗il5纳米抗体及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096704A (en) 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
FR2677654B1 (fr) 1991-06-17 1995-11-17 Pasteur Merieux Serums Vacc Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv.
WO1993023076A1 (en) 1992-05-20 1993-11-25 The Johns-Hopkins University Alternative receptor therapy
US5616488A (en) 1992-12-07 1997-04-01 Ribozyme Pharmaceuticals, Inc. IL-5 targeted ribozymes
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
JP3926839B2 (ja) 1993-09-14 2007-06-06 エピミューン，インコーポレイティド 万能ｄｒ−結合性ペプチドを用いる免疫応答の改変
WO1995026365A1 (en) * 1994-03-28 1995-10-05 United Biomedical, Inc. Synthetic peptide based immunogens for the treatment of allergy
AUPO005496A0 (en) 1996-05-24 1996-06-13 Bresagen Limited An interleukin-5 antagonist
CA2190494C (en) * 1994-05-18 2002-05-07 Michael E. Houston Heterodimer polypeptide immunogen carrier composition and method
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
WO1997000321A1 (en) * 1995-06-14 1997-01-03 Commonwealth Scientific And Industrial Research Organisation Immune response modulators and uses therefor
KR100780158B1 (ko) * 1996-10-23 2007-11-27 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 면역 치료법 및 개량 백신
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
EP1005374B1 (en) 1997-01-22 2007-04-18 Zycos Inc. Microparticles for delivery of nucleic acid
AU7132098A (en) 1997-04-18 1998-11-13 Tanox Biosystems, Inc. Il-5r antagonists for treatment of inflammation, asthma and other allergic diseases
HUP0103976A3 (en) * 1998-10-05 2008-04-28 Pharmexa As Novel methods for therapeutic vaccination

Also Published As

Publication number Publication date
IL145786A0 (en) 2002-07-25
US7285273B1 (en) 2007-10-23
HUP0200958A2 (en) 2002-06-29
EA200101125A1 (ru) 2002-04-25
NO20015021L (no) 2001-12-21
NO20015021D0 (no) 2001-10-15
CZ20013709A3 (cs) 2002-11-13
AU4100800A (en) 2000-11-10
EE200100552A (et) 2002-12-16
KR20020084841A (ko) 2002-11-11
SK14832001A3 (sk) 2003-02-04
WO2000065058A1 (en) 2000-11-02
PL351986A1 (en) 2003-07-14
HRP20010824A2 (en) 2002-12-31
US6746669B1 (en) 2004-06-08
TR200103046T2 (tr) 2002-06-21
AU777952B2 (en) 2004-11-04
HUP0200958A3 (en) 2004-11-29
CA2370391A1 (en) 2000-11-02
EP1173573A1 (en) 2002-01-23
JP2002543098A (ja) 2002-12-17
CN1355846A (zh) 2002-06-26

Similar Documents

Publication Publication Date Title
ZA200109901B (en) Method for down-regulating GDF-8 activity.
PL349010A1 (en) Method for increasing pet activity
HUP0103578A3 (en) Method for down-regulating osteoprotegerin ligand activity
AU3850299A (en) Vegf activity inhibitors
ZA200001333B (en) Method for communicating information.
MXPA01010625A (es) Metodo para regulacion por disminucion de la actividad de interleucina 5.
EP1198306A4 (en) ENCLOSURE METHOD FOR PRESERVING BIO-RENOVABILITY
EP1304573A4 (en) METHOD FOR SCREENING A LIGAND WITH BIOLOGICAL ACTIVITY
GB2362530B (en) Method for improving the wireless location system
HUP0402231A3 (en) A method for determining the biological activity defibrotide
ZA200110053B (en) Factor via inhibitors.
GB0007871D0 (en) Method
GB9902302D0 (en) Detecting enzyume activity
AU6252901A (en) Methods for monitoring enzyme activity
GB2355455B (en) Method
GB0026109D0 (en) An analysis method
IL140058A0 (en) Methods for inhibiting tef-3 activity
GB2347213B (en) Method for determining nuclease activity
GB9921067D0 (en) Activity apparatus
GB0007867D0 (en) Method
SI1114166T1 (en) Method for down-regulating osteoprotegerin ligand activity
GC0000055A (en) Method for making dimethylnaphthalenes.
HU9902898D0 (en) Method for influancing thermosensibility
ZA994986B (en) Analysis system.
GB9917608D0 (en) Activity device